Therapy News and Research

RSS

Standardized protocol enables safer kidney biopsies in high-risk patients

Results from a prospective study reveal that with standardized precautions, even high-risk patients may safely undergo a kidney biopsy, a cornerstone of kidney diagnostics that is often perceived as dangerous in certain vulnerable patient populations.

22 Oct 2026

Potassium binder helps dialysis patients manage dietary restrictions

Dietary potassium restriction is important for managing hyperkalemia, or high blood potassium levels, in individuals on maintenance hemodialysis, but it imposes a substantial day-to-day burden.

22 Oct 2026

New clinical decision support tool aims to improve chronic kidney disease care

Investigators have developed and validated a clinical decision support tool to improve the diagnosis and treatment of chronic kidney disease (CKD) at the point of care. The research will be presented at ASN Kidney Week 2026 October 22–25.

22 Oct 2026

Psilocybin reshapes brain connections through distinct cellular pathways

A new study led by researchers at the University of California, Santa Cruz, reveals how psilocybin, the psychoactive compound in "magic mushrooms," reshapes neural connections in the brain.

22 Oct 2026

Unstable immune cells linked to severe cancer immunotherapy side effects

Scientists at the University of Pittsburgh uncovered the unstable immune cells that can cause up to 40% of immunotherapy patients to experience serious side effects and showed that diet and microbiome composition influence the side effect's severity.

22 Oct 2026

Starting survivorship care earlier improves head and neck cancer survival

Beginning survivorship care for head and neck cancer patients earlier is linked to better survival and lower recurrence, according to a new University of Pittsburgh study published today in JAMA Otolaryngology–Head & Neck Surgery.

22 Oct 2026

Emotion management helps teens maintain weight loss after treatment

Researchers from University of California San Diego have found that adding emotion management skills to family-based behavioral weight management may help adolescents maintain weight loss after treatment ends.

22 Oct 2026

AGA/AASLD joint guideline evaluates newer medications for primary biliary cholangitis

For the first time, a joint guideline from the American Gastroenterological Association (AGA) and American Association for the Study of Liver Diseases (AASLD) evaluates newer medications for primary biliary cholangitis (PBC), the most common cholestatic disease in adults.

22 Oct 2026

Young cancer survivors face critical gaps in follow-up care

Young adult cancer survivors face gaps in follow-up care caused by factors including geographic mobility and insurance changes, according to an analysis by UTHealth Houston researchers.

22 Oct 2026

Half-matched bone marrow transplants show high survival in young aplastic anemia patients

Researchers at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and Johns Hopkins Children's Center report that bone marrow transplant using half-matched family donors achieved a 96% survival rate among children, adolescent, and young adult patients with severe aplastic anemia, a rare, life-threatening disorder in which the bone marrow fails to produce enough healthy blood cells.

22 Oct 2026

Community health workers help patients piece their lives back together

For Georgieanna Pierre-Paul-who wants everyone to call her Gee-the most important part of her job may be a comfortable pair of shoes.

22 Oct 2026

LSD speeds up brain waves and increases neural complexity, study finds

First synthesized in a laboratory in 1938 by the Swiss chemist Albert Hofmann, lysergic acid diethylamide, better known by its acronym LSD, is one of the most potent and most extensively studied psychedelics.

22 Oct 2026

New study explores psychedelic therapy for co-occurring cocaine addiction and depression

A team of UTHealth Houston researchers has been awarded a five-year, $3.4 million grant to study whether psilocybin-assisted therapy is a viable treatment option for individuals with co-occurring cocaine use disorder and major depressive disorder.

22 Oct 2026

INmune Bio establishes global commercialization framework for Ebstrocel™ through strategic agreement with Uniphar

INmune Bio Inc. (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has entered into a Master Services Agreement with Uniphar Durbin Ireland Limited (“Uniphar”) establishing a scalable framework to support international access, distribution and commercialization of Ebstrocel™, the Company’s allogeneic stromal cell therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB).

From INmune Bio 22 Oct 2026

New national trial platform aims to accelerate Alzheimer's disease prevention

Researchers from the University of California San Diego will join a collaboration as part of a federal award of up to $41 million to launch a national effort aimed at accelerating the search for treatments that could prevent or slow Alzheimer's disease.

22 Oct 2026

Stem cell therapies may need new protein quality control standards

Current Good Manufacturing Practice (GMP) standards for cell therapies assess identity, viability, sterility, and genetic stability. For extracellular vesicle (EV) products, Minimal Information for Studies of Extracellular Vesicles (MISEV2023) guidance adds particle size, concentration, markers, morphology, contaminants, endotoxin, and assays.

22 Oct 2026

Review offers guidance for managing recurrent catheter-related bloodstream infections

Patients who depend on long-term intravenous catheters for chemotherapy, hemodialysis, intravenous nutrition and other essential therapies face an ongoing risk of catheter-related bloodstream infections, a potentially life-threatening complication that can be difficult to manage when the device remains necessary for care.

22 Oct 2026

Accelerated TMS cuts depression treatment time from six weeks to three

Transcranial magnetic stimulation (TMS) has proved to be a very effective non-invasive treatment for people with severe depression who have not had success with medication. But traditional TMS has one significant drawback: time.

21 Oct 2026

AI-powered eye tracking could personalize virtual reality therapy for chronic pain

Combining artificial intelligence (AI) with eye tracking in virtual reality could one day help personalize treatment for millions living with chronic pain, according to world-first research from the University of East Anglia.

21 Oct 2026

Semaglutide and teduglutide reduce immune-driven gut injury in mice

Researchers found that gut-derived GLP-1 and GLP-2 signaling helped protect mice against T cell-induced intestinal injury, with GLP-1R primarily regulating inflammation and GLP-2R supporting intestinal repair. Semaglutide and teduglutide, administered separately or together, reduced acute intestinal damage in mice lacking intestinal proglucagon, suggesting potential avenues for investigating treatments for immune-mediated gut injury.

21 Oct 2026